TJP1 and ovarian carcinoma: This highlights a novel role for ZO-1 in modulating the tumor microenvironment and suggests that restoring ZO-1 function or targeting its downstream effectors may represent promising strategies for limiting angiogenesis and disease progression in ovarian cancer.